# Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

> **NCT04878003** · PHASE2 · UNKNOWN · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
- Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

## Interventions

- **DRUG:** KRT-232
- **DRUG:** TL-895

## Key facts

- **NCT ID:** NCT04878003
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-13
- **Primary completion:** 2024-05
- **Final completion:** 2025-10
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878003, "Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04878003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*